Soliciting international perspectives on an American national research agenda for inherited bleeding disorders

References

• Vázquez E, Kim M, Santaella ME. Lived Experience Experts: a name created by us for us. Expert Rev Hematol. 2023;16(S1):7–11. DOI: 10.1080/17474086.2023.2178410.
   Google Scholar
• Valentino LA, Witkop ML, Santaella ME, et al. The National Hemophilia Foundation’s State of the Science Research Summit initiative: the foundation of an inherited bleeding disorders national research blueprint. Expert Rev Hematol. 2023;16(S1):1–5. DOI: 10.1080/17474086.2023.2178412.
   Google Scholar
• Valentino LA, Witkop ML, Santaella ME, et al. Building the blueprint: formulating a community-generated national plan for future research in inherited bleeding disorders. Haemophilia. 2022;28(5):760–768.
   PubMedGoogle Scholar
• Baldwin MK, Ahmadzia HK, Bartlett DL, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research to advance the health of people with inherited bleeding disorders with the potential to menstruate. Expert Rev Hematol. 2023;16(S1):71–86. DOI: 10.1080/17474086.2023.2175660.
   Google Scholar
• Byams VR, Baker JR, Bailey C, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities in health services; diversity, equity, and inclusion; and implementation science. Expert Rev Hematol. 2023;16(S1):87–106. DOI: 10.1080/17474086.2023.2183836.
   Google Scholar
• Nugent D, Acharya SS, Baumann KJ, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for ultra-rare inherited bleeding disorders. Expert Rev Hematol. 2023;16(S1):55–70. DOI: 10.1080/17474086.2023.2175661.
   Google Scholar
• Ragni MV, Young G, Batsuli G, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: facilitating research through infrastructure, workforce, resources and funding. Expert Rev Hematol. 2023;16(S1):107–127. DOI: 10.1080/17474086.2023.2181781.
   Google Scholar
• Sidonio RF Jr., Bryant PC, Di Paola J, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities for mucocutaneous bleeding disorders. Expert Rev Hematol. 2023;16(S1):39–54. DOI: 10.1080/17474086.2023.2171983.
   Google Scholar
• Tran DQ, Benson CC, Boice JA, et al. Building the foundation for a community-generated national research blueprint for inherited bleeding disorders: research priorities to transform the care of people with hemophilia. Expert Rev Hematol. 2023;16(S1):19–37. DOI: 10.1080/17474086.2023.2171981.
   Google Scholar
• Valentino LA, Witkop ML, Santaella ME, et al. The National Hemophilia Foundation State of the Science Research Summit initiative: executive summary. Expert Rev Hematol. 2023;16(S1):129–134. DOI: 10.1080/17474086.2023.2181782.
   Google Scholar
• World Federation of Hemophilia. World Federation of Hemophilia report on the annual global survey 2021. Montréal Canada: WFH; 2022. Available from: https://www1.wfh.org/publications/files/pdf-2324.pdf.
   Google Scholar
• O’Mahony B, Noone D, Prihodova L. Survey of coagulation factor concentrates tender and procurement procedures in 38 European Countries. Haemophilia. 2015;21(4):436–443.
   PubMedGoogle Scholar
• Hamadeh N, Van Rompaey C, Metreau E. New World Bank country classifications by income level: 2021-2022 2021[cited 2022 Dec 28]. Available from: https://blogs.worldbank.org/opendata/new-world-bank-country-classifications-income-level-2021-2022.
   Google Scholar
• Iorio A, Stonebraker JS, Chambost H, et al. Establishing the prevalence and prevalence at birth of hemophilia in males: a meta-analytic approach using national registries. Ann Intern Med. 2019;171(8):540–546.
   PubMed Web of Science ®Google Scholar
• Coffin D, Herr C, O’Hara J, et al. World bleeding disorders registry: the pilot study. Haemophilia. 2018;24(3):e113–e6.
   PubMedGoogle Scholar
• World Federation of Hemophilia. Research and data collection 2023 [cited 2023 Feb 1]. Available from: https://wfh.org/data-collection/#wbdr.
   Google Scholar
• Pierce GF, Adediran M, Diop S, et al. Achieving access to haemophilia care in low-income and lower-middle-income countries: expanded Humanitarian Aid Program of the World Federation of Hemophilia after 5 years. Lancet Haematol. 2022;9(9):e689–e97.
   PubMedGoogle Scholar
• Carcao M, Gouider E, Wu R. Low dose prophylaxis and antifibrinolytics: options to consider with proven benefits for persons with haemophilia. Haemophilia. 2022;28(Suppl 4):26–34.
   PubMedGoogle Scholar
• Chuansumrit A, Sirachainan N, Jaovisidha S, et al. Effectiveness of monthly low dose emicizumab prophylaxis without 4-week loading doses among patients with haemophilia A with and without inhibitors: a case series report. Haemophilia. 2022;29(1):382–5.
   PubMedGoogle Scholar
• Hart DP, Alamelu J, Bhatnagar N, et al. Immune tolerance induction in severe haemophilia A: a UKHCDO inhibitor and paediatric working party consensus update. Haemophilia. 2021;27(6):932–937.
   PubMedGoogle Scholar
• El Ekiaby M, Haffar A. Low-dose surgical prophylaxis: optimization of use of World Federation of Hemophilia Humanitarian Aid donated clotting factor concentrates to developing countries. Haemophilia. 2020;26(Suppl 3):11–15.
   PubMedGoogle Scholar
• Mancuso ME, Apte S, Hermans C. Managing invasive procedures in haemophilia patients with limited resources, extended half-life concentrates or non-replacement therapies in 2022. Haemophilia. 2022;28(Suppl 4):93–102.
   PubMedGoogle Scholar
• Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(Suppl 6):1–158. 3rd
   PubMedGoogle Scholar
• Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv. 2021;5(1):301–325.
   PubMed Web of Science ®Google Scholar
• World Health Organization. Guidance on Increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma 2021[cited 2022 Dec 12]. Available from: https://apps.who.int/iris/handle/10665/340171.
   Google Scholar
• Burnouf T, Epstein J, Faber JC, et al. Stepwise access to safe plasma proteins in resource-constrained countries: local production and pathways to fractionation-report of an international society of blood transfusion workshop. Vox Sang. 2022;117(6):789–795.
   PubMedGoogle Scholar
• Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022;386(11):1013–1025.
   PubMed Web of Science ®Google Scholar
• Reiss UM, Mahlangu J, Ohmori T, et al. Haemophilia gene therapy-Update on new country initiatives. Haemophilia. 2022;28(Suppl 4):61–67.
   PubMedGoogle Scholar
• Chuansumrit A, Parapakpenjune S, Natesirinilkul R, et al. Phenotypic and genotypic analysis of patients with congenital factor VII deficiency in a multicenter study in Thailand. Pedia Hematol Oncol J. 2022;7(4):130–135.
   Google Scholar
• Kandel N, Lamichhane J. Female health volunteers of Nepal: the backbone of health care. Lancet. 2019;393(10171):e19–e20.
   PubMedGoogle Scholar
• Karazivan P, Dumez V, Flora L, et al. The patient-as-partner approach in health care: a conceptual framework for a necessary transition. Acad Med. 2015;90(4):437–441.
   PubMed Web of Science ®Google Scholar
• Baker JR, Crudder SO, Riske B, et al. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health. 2005;95(11):1910–1916.
   PubMedGoogle Scholar
• Hermans C, Noone D, Benson G, et al. Hemophilia treatment in 2021: choosing the”optimal” treatment using an integrative, patient-oriented approach to shared decision-making between patients and clinicians. Blood Rev. 2022;52:100890.
   PubMedGoogle Scholar